Timing of SGLT2i initiation after acute myocardial infarction.

ABSTRACT:

Background

Pharmacological post-MI treatment is routinely initiated at intensive/cardiac care units. However, solid evidence for an early start of these therapies is only available for dual platelet therapy and statins, whereas data on beta blockers and RAAS inhibitors are heterogenous and mainly limited to STEMI and heart failure patients. Recently, the EMMY trial provided the first evidence on the beneficial effects of SGLT2 inhibitors (SGLT2i) when initiated early after PCI. In patients with type 2 diabetes mellitus, SGLT2i are considered "sick days drugs" and it, therefore, remains unclear if very early SGLT2i initiation following MI is as safe and effective as delayed initiation.

Methods and results

The EMMY trial evaluated the effect of empagliflozin on NT-proBNP and f

SUBMITTER: von Lewinski D 

PROVIDER: S-EPMC10544140 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature